NBIX as reported
Neurocrine Biosciences, Inc. reported $3.10B of revenue over the trailing twelve months, +29% on the year before. 10 reported series are charted on this page, each one as filed.
$3.10B
Revenue, trailing twelve months · to Q1 2026 · +29% against the twelve months before
- Net Income
- $669M
Net Income · +119% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $827M
Free Cash Flow · +68% year on year · trailing twelve months to Q1 2026
- Op Margin
- 25%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $3.10B | +29% | Q1 2026 |
| Net Income | $669M | +119% | Q1 2026 |
| EPS | $6.49 | +120% | Q1 2026 |
| Gross Margin | 98% | n/a | Q1 2026 |
| Op Margin | 25% | n/a | Q1 2026 |
| Net Margin | 21% | n/a | Q1 2026 |
| ROE | 15% | n/a | Q1 2026 |
| ROA | 11% | n/a | Q1 2026 |
| Free Cash Flow | $827M | +68% | Q1 2026 |
| P/E | 24.1 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Neurocrine Biosciences, Inc. (NBIX) - Revenue & ProfitRevenue & ProfitNeurocrine Biosciences, Inc. (NBIX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
Ranks #8 of 28 by Smart Score